liver cirrhosis/carbohydrate

Lyen an sove nan clipboard la

Chwazi kalite sòt

12 rezilta yo

Liver and Metabolic Effects of Insulin Pump Therapy in Diabetics Type 2 With Non-alcoholic Hepatic Steatosis

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Change of Adipose Tissues and Triglyceride After Bariatric Surgery or Life-style Intervention

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Obesity is associated with different chronic disorders such as metabolic syndrome, non-alcoholic fatty liver disease (NAFLD) and diabetes mellitus type 2 (DM2). It can be classified into mild, moderate and severe using different cut-off values of body mass index (BMI). Many interventions and

The Effect of Curcumin on Liver Fat Content in Obese Subjects

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The prevalence of obesity is increasing worldwide. Obesity and its associated complications represent an enormous burden for obese individuals, their families, healthcare systems and societies. Non-alcoholic fatty liver disease (NAFLD) has emerged as a frequent and serious complication of obesity.

The Effect Of DAAs on miRNA-122 And Insulin Resistance In Chronic HCV Patients

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The hepatitis C virus (HCV) is an enveloped, single-stranded positive-sense Ribo-Nucleic Acid virus which is a major cause of chronic liver diseases, including cirrhosis and hepatocellular carcinoma (HCC), and infects approximately 3 % of the world population(150-170 million). One of the countries

De Novo Lipogenesis in Severity of NAFLD

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The development of nonalcoholic fatty liver disease (NAFLD) progresses from a state of elevated intrahepatic triglycerides (IHTG) to liver inflammation, and ultimately, hepatic apoptosis and fibrosis. NAFLD is the most prevalent liver disease in the U.S., and there is a serious need to understand

Sarcopenia Improves the Muscle Mass and Muscle Strength of Patients With Liver Cirrhosis-Child C

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Globally, the mortality after any infection in cirrhosis patients is very high. The cumulative mortality in patients with infections was 43.5% (11,987 patients) where as the mortality rate without infection was 13.6% (2317 patients). Over the years, variceal bleeding causing death in cirrhosis has

Lifestyle Intervention in Fatty Liver (NAFLD)

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Background Non-Alcoholic Fatty Liver Disease (NAFLD), including its more pathologic consequence, non-alcoholic steatohepatitis (NASH), is believed to be the most common chronic liver disease worldwide, affecting between 6 to 37% of the population. NAFLD is a so called 'silent killer', as clinical

Effect of Coconut Milk Supplementation to Improve Nutritional Status in Cirrhosis Patient

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

This study investigated the effects of coconut milk supplementation on improving the nutritional status of patients with liver cirrhosis. Design was randomized controlled trial. Investigators randomized the patients into 2 groups. Group I received 25 gram of sugar + 50 cc coconut milk and group II

Efficacy and Safety of High Dose Baclofen for Alcohol Dependence

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Alcohol dependence (AD) is a common problem with significant health consequences. Treatment of AD is evolving to include both counseling methods and medications. Several medications have been discovered, that show efficacy in AD, e.g. naltrexone, acamprosate. However, the overall effect of existing

Resting Energy Expenditure in Patients on the Waiting List for Liver Transplantation

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

This cross-sectional and descriptive study was carried out at the Alfa Institute of Gastroenterology, Hospital of Clinics, Universidade Federal of Minas Gerais (UFMG). The research protocol was approved by the UFMG Ethics Committee. Patients with indication for liver transplantation, aged over 20

Hepatic Metabolism of Galactose and the Galactose Analog FDGal in Patients With Liver Disease and Healthy Subjects

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Antiviral & Antifibrotic Liver Therapy in HCV + Drinkers and Non-Drinkers

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Current therapy for HCV disease focuses on anti-viral treatment. The combination of pegylated interferon and ribavirin is approved by the FDA for treating HCV disease. Subjects in this study will be given ribavirin and pegylated interferon. One innovative aspect of this proposal is that the

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye